Ninlaro (Ixazomib Citrate)

Ixazomib is a reversible proteasome inhibitor. By binding to the 20S proteasome, it blocks the breakdown of polyubiquitinated proteins inside malignant plasma cells. This leads to protein accumulation, cellular stress and ultimately triggers apoptosis, selectively targeting the cancerous cells while sparing most normal tissues.

The dosing regimen for Ninlaro is individualized by the prescribing physician. The prescriber determines the tablet strength, frequency and duration based on the patient’s clinical condition, prior treatments and tolerability, following the approved labeling and local regulatory guidance.

Safety data for ixazomib in pregnancy and lactation are limited. The drug should be used only if the potential benefit justifies the potential risk to the fetus or infant. Women of child‑bearing potential should be advised to use effective contraception during treatment and for a defined period after the last dose.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Ninlaro. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative proteasome inhibitor is bortezomib, which is administered by injection. Ninlaro offers an oral formulation, providing greater convenience and potentially improved adherence. Both agents share a similar mechanism of proteasome inhibition, but differences in pharmacokinetics, side‑effect profiles and administration routes influence clinical choice.

Ninlaro tablets should be stored at ambient temperature, below 25 °C (77 °F). Keep the product in its original blister pack, protect it from moisture and direct sunlight, and ensure the container is tightly closed when not in use to maintain stability.

Ninlaro is taken orally as a tablet, usually on an empty stomach (at least one hour before or after food). The tablet should be swallowed whole with a glass of water; it should not be crushed, chewed, or split unless specifically instructed by a healthcare professional.

Serious adverse events include severe neutropenia, which can predispose to life‑threatening infections, thrombocytopenia that may cause significant bleeding, pulmonary embolism, and cardiac failure. Patients should be monitored closely for signs of infection, unexplained bruising, shortness of breath, or swelling, and report any concerns promptly.

Ninlaro is contraindicated in patients with known hypersensitivity to ixazomib or any of its excipients. It should be avoided in individuals with uncontrolled infections, severe cardiac disease, or those who are pregnant unless the potential benefit outweighs the risk. Clinicians must also consider drug‑specific cautions for patients with impaired hepatic function.